Justices reject holding generic pharmaceutical manufacturers liable for decisions of pharmacists about prescribing their products

The U.S. Supreme Court, in a unanimous decision in *Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc.*, clarified the standard for induced patent infringement under 35 U.S.C. § 271(b) in the context of generic drug "skinny labels." The Court held that a generic manufacturer cannot be held liable for induced infringement based on general communications, such as its FDA-approved skinny label, website content, or press releases, unless the patent holder plausibly alleges that the generic company took "active steps" to encourage the patented use. This decision reverses the Federal Circuit and reinforces that mere possibility of physician interpretation is insufficient; rather, affirmative, culpable conduct designed to induce infringement must be shown, providing significant clarity for generic drug manufacturers operating under the Hatch-Waxman Act.

The U.S. Supreme Court recently delivered a landmark unanimous decision in *Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc.*, significantly impacting the landscape of patent law for pharmaceutical companies. This ruling addresses the contentious issue of induced patent infringement, particularly concerning generic drug manufacturers utilizing "skinny labels" under the Hatch-Waxman Act. The Court's decision, authored by Justice Ketanji Brown Jackson, provides crucial guidance on the evidentiary threshold required to establish active inducement, rejecting the notion that generic manufacturers can be held liable based on the mere possibility that healthcare providers might interpret their lawful communications as encouragement to infringe a patented method of use.

At its core, the case asked the Supreme Court to delineate the line between legitimate generic competition and actionable inducement of infringement. The Court's holding unequivocally favors generic manufacturers, reinforcing that the statutory framework for generic drug approval, including the use of carved-out labels, is intended to foster competition. This decision has profound implications for both branded pharmaceutical innovators seeking to protect their method-of-use patents and generic companies navigating the complexities of FDA approval and market entry, by clarifying the scope of liability for communications surrounding generic products.

The central thesis of this article is that the Supreme Court's ruling in *Hikma v. Amarin* tightens the pleading standard for induced infringement claims against generic drug manufacturers, demanding concrete evidence of affirmative encouragement rather than speculative interpretations of routine industry communications. This recalibration of the inducement analysis provides greater certainty for generic companies while setting a higher bar for patentees to prove culpable conduct.

Understanding the *Hikma v. Amarin* decision requires an appreciation of the statutory and doctrinal context of pharmaceutical patent law in the United States. The Hatch-Waxman Act (officially the Drug Price Competition and Patent Term Restoration Act of 1984) created an abbreviated pathway for generic drug approval through Abbreviated New Drug Applications (ANDAs), aiming to balance innovation incentives with timely access to affordable generic medicines. A key feature of this framework is the "skinny label" provision, which allows generic manufacturers to "carve out" patented indications from their product labels, thereby seeking FDA approval only for unpatented uses.

Induced patent infringement is governed by 35 U.S.C. § 271(b), which states that "Whoever actively induces infringement of a patent shall be liable as an infringer." To establish induced infringement, a plaintiff must prove three elements: (1) direct infringement by a third party, (2) the alleged inducer's knowledge that the induced acts constitute patent infringement, and (3) the alleged inducer's "active steps" to encourage that direct infringement. The "active steps" requirement, particularly in the context of generic drug labeling and marketing, has been a source of significant litigation and uncertainty, especially after the Federal Circuit's prior interpretations that sometimes allowed claims to proceed based on how a physician *could* interpret a generic's statements.

The dispute in *Hikma v. Amarin* arose from Amarin's brand-name drug, Vascepa® (icosapent ethyl), which had two FDA-approved indications: an unpatented indication for severe hypertriglyceridemia (SH indication) and a later-patented indication for reducing cardiovascular risk (CV indication). Hikma, a generic manufacturer, sought and obtained FDA approval for its generic icosapent ethyl using a skinny label that carved out the patented CV indication, listing only the unpatented SH indication. Amarin subsequently sued Hikma, alleging that Hikma's overall conduct, including its skinny label, patient information leaflet, website, and press releases, actively induced healthcare providers to prescribe the generic for the patented CV indication.

The Supreme Court's unanimous decision in *Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc.* reversed the Federal Circuit, holding that Amarin failed to plausibly allege induced infringement. Justice Jackson, writing for the Court, emphasized that the "central question" for induced infringement under 35 U.S.C. § 271(b) is whether the generic manufacturer *actively encouraged* infringing use, not merely whether doctors *could plausibly read* alleged statements as instructions to infringe. This distinction is critical, shifting the focus from the potential interpretation by third-party prescribers to the affirmative conduct and intent of the alleged inducer.

The Court clarified that "active steps" to encourage direct infringement requires "affirmative, culpable conduct." It rejected Amarin's arguments that Hikma's statements, such as touting its product as a "generic equivalent" to Vascepa® or referencing the brand's sales figures (which were largely attributable to the patented CV indication), constituted such active encouragement. The Court reasoned that these statements had "an obvious alternative explanation," namely, compliance with federal labeling requirements or standard industry practice. For instance, the "duty of sameness" under the Hatch-Waxman Act often requires generic labels to mirror the brand-name label, apart from the carved-out indication.

Furthermore, the Supreme Court explicitly rejected theories of inducement grounded in "mere omissions, inactions, or nonfeasance." Amarin had argued that Hikma's failure to highlight the limited scope of its approval or to include "Limitation of Use" language regarding the patented use should be considered. However, the Court found that patient leaflets referencing cardiovascular conditions, website descriptions of therapeutic categories, or press releases including aggregate sales figures were too attenuated and speculative to plausibly support liability. This reinforces that generic manufacturers are not obligated to actively dissuade off-label use of their products, provided their own communications do not affirmatively encourage patented uses.

This decision aligns with the principle that inducement, whether express or implied, "must be clear to the relevant audience and affirmative." It underscores that routine generic communications, including equivalence statements and labeling that mirrors the reference listed drug apart from the carve-out, are considered "ordinary acts incident to product distribution" and cannot, without more, support inducement liability. The Court's analysis effectively raises the bar for pleading induced infringement, requiring patentees to demonstrate concrete evidence of the generic manufacturer's specific intent and active encouragement of the patented use, rather than relying on broad interpretations of general marketing materials or the potential for off-label prescribing by physicians.

The Supreme Court's unanimous decision in *Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc.* marks a significant victory for generic pharmaceutical manufacturers and provides much-needed clarity regarding the scope of induced patent infringement liability under 35 U.S.C. § 271(b). By emphasizing the requirement for "active steps" and "affirmative, culpable conduct" to encourage infringement, the Court has curtailed the ability of branded drug companies to pursue induced infringement claims based on attenuated allegations concerning "skinny labels" and routine generic communications. This ruling strengthens the viability of the Hatch-Waxman Act's carve-out provisions, promoting generic competition and access to more affordable medicines.

For practitioners, this decision underscores the importance of meticulously scrutinizing the specific communications and actions of generic manufacturers when assessing potential induced infringement claims. Patentees must now present plausible allegations of clear and affirmative encouragement of the patented use, moving beyond speculative interpretations of a generic's compliance with regulatory requirements or standard industry practices. Conversely, generic manufacturers can proceed with greater confidence in their "skinny label" strategies, provided their communications do not overtly promote or encourage patented indications. While the Court affirmed that inducement liability remains a meaningful protection for innovators, the bar for proving such liability has been definitively raised, necessitating a strategic re-evaluation of litigation approaches for both sides of the pharmaceutical patent divide.